Esomeprazole 20 mg on‐demand is more acceptable to patients than continuous lansoprazole 15 mg in the long‐term maintenance of endoscopy‐negative gastro‐oesophageal reflux patients: the COMMAND Study
Summary Background : Symptom relief, through adherence to appropriate maintenance therapy, is the sole objective of treatment for patients with endoscopy‐negative gastro‐oesophageal reflux disease. Aim : To compare the efficacy of ‘on‐demand’ treatment with esomeprazole 20 mg vs. continuous treatmen...
Saved in:
Published in: | Alimentary pharmacology & therapeutics Vol. 20; no. 6; pp. 657 - 665 |
---|---|
Main Authors: | , , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
Oxford, UK
Blackwell Science Ltd
15-09-2004
Blackwell |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Abstract | Summary
Background : Symptom relief, through adherence to appropriate maintenance therapy, is the sole objective of treatment for patients with endoscopy‐negative gastro‐oesophageal reflux disease.
Aim : To compare the efficacy of ‘on‐demand’ treatment with esomeprazole 20 mg vs. continuous treatment with lansoprazole 15 mg daily in patients with endoscopy‐negative gastro‐oesophageal reflux disease.
Methods : Endoscopy‐negative gastro‐oesophageal reflux disease patients who achieved complete resolution of heartburn after short‐term (2–4 weeks) treatment with esomeprazole 20 mg (n = 774) were randomized to receive either esomeprazole 20 mg on‐demand (n =311) or lansoprazole 15 mg continuous daily treatment (n = 311) for 6 months.
Results : Significantly more patients were willing to continue taking esomeprazole on‐demand than lansoprazole continuous therapy after 6 months (93% vs. 88%; P = 0.02). This superior outcome was achieved despite patients on esomeprazole requiring medication only 38% as often as those on lansoprazole, leading to direct cost savings of more than one‐third (36%). Furthermore, patients receiving esomeprazole 20 mg on‐demand were more satisfied with their treatment after 1 month compared with patients taking lansoprazole 15 mg continuously.
Conclusions : In patients with endoscopy‐negative gastro‐oesophageal reflux disease, esomeprazole 20 mg on‐demand is more acceptable to patients and is an economically more effective treatment than lansoprazole 15 mg continuously. |
---|---|
AbstractList | Background
: Symptom relief, through adherence to appropriate maintenance therapy, is the sole objective of treatment for patients with endoscopy‐negative gastro‐oesophageal reflux disease.
Aim
: To compare the efficacy of ‘on‐demand’ treatment with esomeprazole 20 mg vs. continuous treatment with lansoprazole 15 mg daily in patients with endoscopy‐negative gastro‐oesophageal reflux disease.
Methods
: Endoscopy‐negative gastro‐oesophageal reflux disease patients who achieved complete resolution of heartburn after short‐term (2–4 weeks) treatment with esomeprazole 20 mg (
n
= 774) were randomized to receive either esomeprazole 20 mg on‐demand (
n
=311) or lansoprazole 15 mg continuous daily treatment (
n
= 311) for 6 months.
Results
: Significantly more patients were willing to continue taking esomeprazole on‐demand than lansoprazole continuous therapy after 6 months (93% vs. 88%;
P
= 0.02). This superior outcome was achieved despite patients on esomeprazole requiring medication only 38% as often as those on lansoprazole, leading to direct cost savings of more than one‐third (36%). Furthermore, patients receiving esomeprazole 20 mg on‐demand were more satisfied with their treatment after 1 month compared with patients taking lansoprazole 15 mg continuously.
Conclusions
: In patients with endoscopy‐negative gastro‐oesophageal reflux disease, esomeprazole 20 mg on‐demand is more acceptable to patients and is an economically more effective treatment than lansoprazole 15 mg continuously. Summary Background : Symptom relief, through adherence to appropriate maintenance therapy, is the sole objective of treatment for patients with endoscopy‐negative gastro‐oesophageal reflux disease. Aim : To compare the efficacy of ‘on‐demand’ treatment with esomeprazole 20 mg vs. continuous treatment with lansoprazole 15 mg daily in patients with endoscopy‐negative gastro‐oesophageal reflux disease. Methods : Endoscopy‐negative gastro‐oesophageal reflux disease patients who achieved complete resolution of heartburn after short‐term (2–4 weeks) treatment with esomeprazole 20 mg (n = 774) were randomized to receive either esomeprazole 20 mg on‐demand (n =311) or lansoprazole 15 mg continuous daily treatment (n = 311) for 6 months. Results : Significantly more patients were willing to continue taking esomeprazole on‐demand than lansoprazole continuous therapy after 6 months (93% vs. 88%; P = 0.02). This superior outcome was achieved despite patients on esomeprazole requiring medication only 38% as often as those on lansoprazole, leading to direct cost savings of more than one‐third (36%). Furthermore, patients receiving esomeprazole 20 mg on‐demand were more satisfied with their treatment after 1 month compared with patients taking lansoprazole 15 mg continuously. Conclusions : In patients with endoscopy‐negative gastro‐oesophageal reflux disease, esomeprazole 20 mg on‐demand is more acceptable to patients and is an economically more effective treatment than lansoprazole 15 mg continuously. Symptom relief, through adherence to appropriate maintenance therapy, is the sole objective of treatment for patients with endoscopy-negative gastro-oesophageal reflux disease. To compare the efficacy of 'on-demand' treatment with esomeprazole 20 mg vs. continuous treatment with lansoprazole 15 mg daily in patients with endoscopy-negative gastro-oesophageal reflux disease. Endoscopy-negative gastro-oesophageal reflux disease patients who achieved complete resolution of heartburn after short-term (2-4 weeks) treatment with esomeprazole 20 mg (n = 774) were randomized to receive either esomeprazole 20 mg on-demand (n =311) or lansoprazole 15 mg continuous daily treatment (n = 311) for 6 months. Significantly more patients were willing to continue taking esomeprazole on-demand than lansoprazole continuous therapy after 6 months (93% vs. 88%; P = 0.02). This superior outcome was achieved despite patients on esomeprazole requiring medication only 38% as often as those on lansoprazole, leading to direct cost savings of more than one-third (36%). Furthermore, patients receiving esomeprazole 20 mg on-demand were more satisfied with their treatment after 1 month compared with patients taking lansoprazole 15 mg continuously. In patients with endoscopy-negative gastro-oesophageal reflux disease, esomeprazole 20 mg on-demand is more acceptable to patients and is an economically more effective treatment than lansoprazole 15 mg continuously. |
Author | Duggan, S. Vearer, D. Rosen, J. P. Chapman, R. Shepherd, A. McKeith, D. Anderson, M. Tsai, H. H. |
Author_xml | – sequence: 1 givenname: H. H. surname: Tsai fullname: Tsai, H. H. – sequence: 2 givenname: R. surname: Chapman fullname: Chapman, R. – sequence: 3 givenname: A. surname: Shepherd fullname: Shepherd, A. – sequence: 4 givenname: D. surname: McKeith fullname: McKeith, D. – sequence: 5 givenname: M. surname: Anderson fullname: Anderson, M. – sequence: 6 givenname: D. surname: Vearer fullname: Vearer, D. – sequence: 7 givenname: S. surname: Duggan fullname: Duggan, S. – sequence: 8 givenname: J. P. surname: Rosen fullname: Rosen, J. P. |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16098821$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/15352914$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkc9u1DAQhy1URLeFV0C-cEywnTh_kDisllKQWopEOVsTZzbNKrGj2IHdnirxArwbb9Anweku7RVfbHm--TSa3wk5MtYgIZSzmIfzdhPzJJORYEkWC8bSmAkuZbx9RhaPhSOyYCIrI1Hw5JicOLdhjGU5Ey_IMZeJFCVPF-TPmbM9DiPc2g6pYPd3v_qGWnN_97vGHkxNW0d7OyIFrXHwUAXMWzqAb9F4R_0NGKqt8a2Z7ORoB8bZfz4u977WBA5pZ00TxB7HnvbQGo8GjEZq1xRNbZ22wy7UDTbB_gNpA86PNvxYDM4baBA6OuK6m7aPA7x7MK-uLi-XXz7Qb36qdy_J8zV0Dl8d7lPy_ePZ9epTdHF1_nm1vIi05FxGMmFQlxoqLkpMWIqaF5BhCjKvINMVZjXL87ysUl2JShQ6K4SQPBc8bBvrIjklxd6rR-tcmEsNY9vDuFOcqTkntVFzHGqOQ805qYec1Da0vt63DlPVY_3UeAgmAG8OADgN3XoMi2rdE5exsigED9z7Pfez7XD33wOo5dfr-ZX8BT5aulg |
CitedBy_id | crossref_primary_10_1007_s12171_007_0027_8 crossref_primary_10_1590_S0004_28032010000100017 crossref_primary_10_1111_j_1572_0241_2007_01106_x crossref_primary_10_1590_S0104_42302011000600006 crossref_primary_10_4137_CMT_S4500 crossref_primary_10_3748_wjg_v11_i28_4291 crossref_primary_10_2165_00003495_200868110_00009 crossref_primary_10_3748_wjg_v21_i22_6965 crossref_primary_10_1007_s00535_016_1227_8 crossref_primary_10_1111_j_1365_2036_2005_02637_x crossref_primary_10_1007_s12328_010_0139_z crossref_primary_10_1111_j_1365_2036_2005_02611_x crossref_primary_10_1002_14651858_CD011969_pub2 crossref_primary_10_3109_00365521_2013_878380 crossref_primary_10_1097_00042737_200509000_00009 crossref_primary_10_1159_000327533 crossref_primary_10_1586_1744666X_1_4_511 crossref_primary_10_1007_s11938_007_0073_4 crossref_primary_10_1517_17425250903124363 crossref_primary_10_1016_j_curtheres_2005_08_012 crossref_primary_10_1111_j_1440_1746_2007_05249_x crossref_primary_10_1155_2018_6417526 crossref_primary_10_1016_S2255_4823_11_70124_2 crossref_primary_10_1016_S0104_4230_11_70124_5 crossref_primary_10_1111_j_1365_2036_2007_03381_x crossref_primary_10_5056_jnm21095 crossref_primary_10_1097_MD_0000000000012732 crossref_primary_10_2147_ciia_2007_2_1_85 crossref_primary_10_1111_j_1365_2036_2010_04544_x crossref_primary_10_1016_j_cgh_2024_05_004 crossref_primary_10_1016_j_jval_2013_01_007 crossref_primary_10_1038_nrgastro_2013_50 crossref_primary_10_1185_03007995_2015_1047745 crossref_primary_10_1016_S0399_8320_07_89329_8 crossref_primary_10_2165_00003495_200868070_00004 crossref_primary_10_1053_j_gastro_2008_08_044 crossref_primary_10_1016_j_bpg_2010_09_004 crossref_primary_10_1186_s12876_016_0448_x crossref_primary_10_2165_00003495_200565001_00007 crossref_primary_10_1590_s0004_2803_24612023_154 crossref_primary_10_4166_kjg_2012_60_4_195 crossref_primary_10_1007_s11938_008_0005_y crossref_primary_10_1111_j_1365_2036_2005_02490_x crossref_primary_10_1517_14656566_7_1_47 |
Cites_doi | 10.1136/gut.44.2008.S1 10.1046/j.1365-2036.2003.01423.x 10.3109/00365528909091032 10.1046/j.1365-2036.17.s2.5.x 10.1159/000200911 10.1046/j.1365-2036.2003.01464.x 10.1046/j.1365-2036.2000.00813.x 10.1097/00042737-200208000-00008 10.1016/0895-4356(94)90036-1 10.1007/BF03022115 10.1046/j.1365-2036.2001.00943.x |
ContentType | Journal Article |
Copyright | 2004 INIST-CNRS |
Copyright_xml | – notice: 2004 INIST-CNRS |
CorporateAuthor | COMMAND Study Group |
CorporateAuthor_xml | – name: COMMAND Study Group |
DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION |
DOI | 10.1111/j.1365-2036.2004.02155.x |
DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef |
DatabaseTitleList | CrossRef MEDLINE |
Database_xml | – sequence: 1 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1365-2036 |
EndPage | 665 |
ExternalDocumentID | 10_1111_j_1365_2036_2004_02155_x 15352914 16098821 APT2155 |
Genre | article Multicenter Study Comparative Study Clinical Trial Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- .3N .GA .GJ .Y3 05W 0R~ 10A 1OB 1OC 23M 24P 31~ 33P 36B 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5VS 66C 6J9 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAKAS AANLZ AAONW AASGY AAXRX AAZKR ABCQN ABCUV ABDBF ABEML ABJNI ABOCM ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACGOF ACMXC ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZCM ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFPM AFGKR AFPWT AFRAH AFZJQ AHBTC AHEFC AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BAWUL BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF D-6 D-7 D-E D-F DC6 DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM DTERQ E3Z EAD EAP EAS EBC EBD EBS EBX EJD EMB EMK EMOBN EST ESX EX3 F00 F01 F04 F5P FEDTE FIJ FUBAC FZ0 G-S G.N GODZA GX1 H.X HF~ HGLYW HVGLF HZI HZ~ IHE IPNFZ IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK0 MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D P6G PALCI Q.N Q11 QB0 Q~Q R.K RIWAO RJQFR ROL RX1 SAMSI SUPJJ SV3 TEORI TR2 TUS UB1 V8K V9Y W8V W99 WBKPD WH7 WHWMO WIH WIJ WIK WIN WOHZO WOW WQJ WRC WUP WVDHM WXI WXSBR XG1 YOC ZZTAW ~IA ~WT AAJUZ AAVGM ABCVL ABHUG ABPTK ACXME ADAWD ADDAD AFVGU AGJLS IQODW ZA5 CGR CUY CVF ECM EIF NPM AAMNL AAYXX CITATION |
ID | FETCH-LOGICAL-c5115-530ad9cab129e304ec18a6e4a57ba6cbe6d07779b4cb2b28c682251721021ed83 |
IEDL.DBID | 33P |
ISSN | 0269-2813 |
IngestDate | Fri Nov 22 00:17:49 EST 2024 Sat Sep 28 07:46:35 EDT 2024 Sun Oct 22 16:05:54 EDT 2023 Sat Aug 24 00:51:47 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 6 |
Keywords | Human Gastroesophageal reflux Enzyme Esophageal disease H Enzyme inhibitor Antiulcer agent K Long term Proton pump inhibitor Benzimidazole derivatives Antisecretory agent Esomeprazole Digestive diseases exchanging ATPase Hydrolases Endoscopy Lansoprazole |
Language | English |
License | CC BY 4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c5115-530ad9cab129e304ec18a6e4a57ba6cbe6d07779b4cb2b28c682251721021ed83 |
OpenAccessLink | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1365-2036.2004.02155.x |
PMID | 15352914 |
PageCount | 9 |
ParticipantIDs | crossref_primary_10_1111_j_1365_2036_2004_02155_x pubmed_primary_15352914 pascalfrancis_primary_16098821 wiley_primary_10_1111_j_1365_2036_2004_02155_x_APT2155 |
PublicationCentury | 2000 |
PublicationDate | 2004-09-15 |
PublicationDateYYYYMMDD | 2004-09-15 |
PublicationDate_xml | – month: 09 year: 2004 text: 2004-09-15 day: 15 |
PublicationDecade | 2000 |
PublicationPlace | Oxford, UK |
PublicationPlace_xml | – name: Oxford, UK – name: Oxford – name: England |
PublicationTitle | Alimentary pharmacology & therapeutics |
PublicationTitleAlternate | Aliment Pharmacol Ther |
PublicationYear | 2004 |
Publisher | Blackwell Science Ltd Blackwell |
Publisher_xml | – name: Blackwell Science Ltd – name: Blackwell |
References | 2002; 14 1989; 156 2000; 14 2001 2000 2002; 51 1999; 49 2000; 30 2000; 7 1999; 44 1994; 47 2003; 17 2001; 15 2001; 13 1998; 42 1992; 51 e_1_2_13_12_2 Hungin APS (e_1_2_13_15_2) 1999; 49 e_1_2_13_13_2 e_1_2_13_20_2 e_1_2_13_11_2 e_1_2_13_8_2 e_1_2_13_7_2 e_1_2_13_6_2 Quigley EMM. (e_1_2_13_5_2) 2001; 13 Talley NJ (e_1_2_13_14_2) 2002; 51 Hungin APS (e_1_2_13_10_2) 1999; 49 e_1_2_13_9_2 Baldi F (e_1_2_13_18_2) 2000; 7 e_1_2_13_4_2 e_1_2_13_3_2 e_1_2_13_2_2 Roseveare C (e_1_2_13_17_2) 1998; 42 e_1_2_13_16_2 e_1_2_13_19_2 |
References_xml | – volume: 14 start-page: 861 year: 2000 end-page: 7 article-title: Esomeprazole provides improved acid control vs. omeprazole inpatients with symptoms of gastro‐oesophageal reflux disease publication-title: Aliment Pharmacol Ther – volume: 42 issue: Suppl. 1 year: 1998 article-title: Alternative day and prn lansoprazole in the maintenance treatment of oesophagitis publication-title: Gut – volume: 15 start-page: 347 year: 2001 end-page: 54 article-title: Esomeprazole 20 mg maintains symptom control in endoscopy‐negative gastro‐oesophageal reflux disease: a controlled trial of ‘on‐demand’ therapy for 6 months publication-title: Aliment Pharmacol Ther – volume: 156 start-page: 7 issue: Suppl. year: 1989 end-page: 13 article-title: Epidemiology of reflux disease and reflux esophagitis publication-title: Scand J Gastroenterol – volume: 51 start-page: 24 issue: Suppl. 1 year: 1992 end-page: 49 article-title: Epidemiology and natural history of gastro‐oesophageal reflux disease publication-title: Digestion – volume: 13 start-page: S19 issue: Suppl. 1 year: 2001 end-page: 8 article-title: Non‐erosive reflux disease: part of the spectrum of gastro‐oesophageal reflux disease, a component of functional dyspepsia, or both publication-title: Eur J Gastroenterol Hepatol – volume: 51 start-page: A230 issue: Suppl. III year: 2002 article-title: Predictors of treatment response in patients with non‐erosive reflux disease (NERD) publication-title: Gut – volume: 49 start-page: 463 year: 1999 end-page: 4 article-title: Factors influencing compliance in long‐term proton pump inhibitor therapy in general practice publication-title: Br J Gen Pract – year: 2001 – volume: 47 start-page: 81 year: 1994 end-page: 87 article-title: Determining the minimal important change in a disease‐specific quality of life questionnaire publication-title: J Clin Epidemiol – volume: 30 start-page: 243 year: 2000 end-page: 53 article-title: Prevention of relapse of gastro‐oesophageal reflux disease by lansoprazole: 30 mg every other day or 15 mg daily publication-title: Acta Endoscopica – year: 2000 – volume: 17 start-page: 52 issue: Suppl. 2 year: 2003 end-page: 6 article-title: Review article: Management of mild and severe gastro‐oesophageal reflux disease publication-title: Aliment Pharmacol Ther – volume: 7 start-page: 17 issue: Special Issue 1 year: 2000 end-page: 23 article-title: Efficacy and tolerability of lansoprazole 15 mg as maintenance therapy of GORD publication-title: Dis Manage Health Outcomes – volume: 17 start-page: 537 year: 2003 end-page: 45 article-title: Non‐erosive reflux disease (NERD) acid reflux and symptom patterns publication-title: Aliment Pharmacol Ther – volume: 44 start-page: S1 issue: Suppl. 2 year: 1999 end-page: S16 article-title: An evidence‐based appraisal of reflux disease management the Geneval Workshop Report publication-title: Gut – volume: 14 start-page: 857 year: 2002 end-page: 63 article-title: Esomeprazole 40 mg and 20 mg is efficacious in the long‐term management of patients with endoscopy‐negative gastro‐oesophageal reflux disease: a placebo‐controlled trial of on‐demand therapy for 6 months publication-title: Eur J Gastroenterol Hepatol – volume: 49 start-page: 451 year: 1999 end-page: 3 article-title: Long‐term prescribing of proton pump inhibitors in general practice publication-title: Br J Gen Pract – volume: 17 start-page: 333 year: 2003 end-page: 41 article-title: Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results publication-title: Aliment Pharmacol Ther – ident: e_1_2_13_9_2 doi: 10.1136/gut.44.2008.S1 – ident: e_1_2_13_4_2 doi: 10.1046/j.1365-2036.2003.01423.x – volume: 49 start-page: 451 year: 1999 ident: e_1_2_13_10_2 article-title: Long‐term prescribing of proton pump inhibitors in general practice publication-title: Br J Gen Pract contributor: fullname: Hungin APS – ident: e_1_2_13_16_2 – ident: e_1_2_13_3_2 doi: 10.3109/00365528909091032 – ident: e_1_2_13_6_2 doi: 10.1046/j.1365-2036.17.s2.5.x – ident: e_1_2_13_2_2 doi: 10.1159/000200911 – ident: e_1_2_13_12_2 doi: 10.1046/j.1365-2036.2003.01464.x – volume: 7 start-page: 17 issue: 1 year: 2000 ident: e_1_2_13_18_2 article-title: Efficacy and tolerability of lansoprazole 15 mg as maintenance therapy of GORD publication-title: Dis Manage Health Outcomes contributor: fullname: Baldi F – ident: e_1_2_13_11_2 doi: 10.1046/j.1365-2036.2000.00813.x – volume: 42 issue: 1 year: 1998 ident: e_1_2_13_17_2 article-title: Alternative day and prn lansoprazole in the maintenance treatment of oesophagitis publication-title: Gut contributor: fullname: Roseveare C – ident: e_1_2_13_7_2 doi: 10.1097/00042737-200208000-00008 – ident: e_1_2_13_13_2 doi: 10.1016/0895-4356(94)90036-1 – volume: 49 start-page: 463 year: 1999 ident: e_1_2_13_15_2 article-title: Factors influencing compliance in long‐term proton pump inhibitor therapy in general practice publication-title: Br J Gen Pract contributor: fullname: Hungin APS – ident: e_1_2_13_19_2 doi: 10.1007/BF03022115 – ident: e_1_2_13_20_2 – ident: e_1_2_13_8_2 doi: 10.1046/j.1365-2036.2001.00943.x – volume: 51 start-page: A230 year: 2002 ident: e_1_2_13_14_2 article-title: Predictors of treatment response in patients with non‐erosive reflux disease (NERD) publication-title: Gut contributor: fullname: Talley NJ – volume: 13 start-page: S19 issue: 1 year: 2001 ident: e_1_2_13_5_2 article-title: Non‐erosive reflux disease: part of the spectrum of gastro‐oesophageal reflux disease, a component of functional dyspepsia, or both publication-title: Eur J Gastroenterol Hepatol contributor: fullname: Quigley EMM. |
SSID | ssj0006702 |
Score | 2.0234816 |
Snippet | Summary
Background : Symptom relief, through adherence to appropriate maintenance therapy, is the sole objective of treatment for patients with... Symptom relief, through adherence to appropriate maintenance therapy, is the sole objective of treatment for patients with endoscopy-negative... Background : Symptom relief, through adherence to appropriate maintenance therapy, is the sole objective of treatment for patients with endoscopy‐negative... |
SourceID | crossref pubmed pascalfrancis wiley |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 657 |
SubjectTerms | 2-Pyridinylmethylsulfinylbenzimidazoles Adolescent Adult Aged Aged, 80 and over Anti-Ulcer Agents - administration & dosage Anti-Ulcer Agents - adverse effects Biological and medical sciences Digestive system Esomeprazole - administration & dosage Esomeprazole - adverse effects Esomeprazole - analogs & derivatives Gastroenterology. Liver. Pancreas. Abdomen Gastroesophageal Reflux - drug therapy Humans Lansoprazole Medical sciences Middle Aged Patient Satisfaction Pharmacology. Drug treatments Single-Blind Method Treatment Outcome |
Title | Esomeprazole 20 mg on‐demand is more acceptable to patients than continuous lansoprazole 15 mg in the long‐term maintenance of endoscopy‐negative gastro‐oesophageal reflux patients: the COMMAND Study |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1365-2036.2004.02155.x https://www.ncbi.nlm.nih.gov/pubmed/15352914 |
Volume | 20 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1fa9swEBdbH8ZgbN2_LvtT9LBXFyuWLHtvoUlpN9IV1sHezMlWQiCRQhxDu6fCvsC-275BP8nu5CRNYA9j7MUYyzrbOkl3J__uJ8beqxF0lQWIpFUqkiMVR5BoHcWlzCqpBMSBMv_0iz7_lvUHRJPzcZ0L0_JDbBbcaGSE-ZoGOJh6d5AHhBZOwSHMOyLrpY7In8SgIWRzJBebSTnVAX6IEUcedTOR7IJ6_ihox1I9mkONjTZqd7vYMlfbLm2wSSdP_ufX7LPHK8-U99qu9JTds-4ZezBc_Xt_zn4Naj-z8wV891PLu_HtzY_ZmHt3e_OzsjNwFZ_UnGC7HErCylBOFl96vmJurTkt0nOCxk9c45uaT9FK-rU8oVp5E4f3WT71boyCyW7wGRCnBRGDWO5H3LrKUy7NNZY7Ow7E5XwM9XLh8Yq3tC8DTpL4Kdik0-Zq8wIfguTjz8Nh77zPCUB5_YJ9PRlcHp9Gqy0hohI9QxWpJIYqL8Ggm2KTWNpSZJBaCUobSEtj0yrWWudGlqZrulmZogOkKMzF9rRVlrxke847-4pxJYxOrMk1oIej0UsUWCuVygijoDKmw8Ra_cW8Zf4otiIm1FZB2qJ9PGURtFVcddjhTj-5q5jGOcYyosMO2o5zV0L8OrmQHZaG_vHXzyp6F5d09vpfK75hD1sYUh4J9ZbtLReNfcfu11VzGMYOHvtnn34Dxr4fIQ |
link.rule.ids | 315,782,786,1408,27934,27935,46065,46489 |
linkProvider | Wiley-Blackwell |
linkToHtml | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3datswFBZbB9ugdP9ruq3TxW5dLFuy7N2FNiWjTVZYBrszkq2EQCKFOIa2V4W-wN5tb9An2TlykiawizF2Zyzr2NL5l48-EfJJDFUkjFIBN0IEfCjCQMVSBmHB05ILpkIPmd_9Jvs_0pMOwuScrfbCNPgQ6wU31Axvr1HBcUF6W8t9iRbYYJ_nHaH7EkcQUD7iCU9RxOP4Ym2WE-kLECHnyIIoZfF2Wc8fKW35qt2ZqmDahs15FxsOazOo9V7p9Nl_Hc9zsrcMTmm7kaYX5IGxL8nj3vL3-yvyq1O5qZnN1bWbGBqFdze30xF19u7mZ2mmypZ0XFGs3KWqwHIZ3JZFF44uwVsriuv0FKvjx7Z2dUUn4Cjdih4TDb2xhecMnTg7AsLoOuhUIawFYoMY6obU2NLhdporaLdm5LHL6UhVi7mDO87g0QxgJ2EoMKeT-nL9AZ895eOvvV67f0KxhvLqNfl-2hkcd4PlqRBBAcGhCEQcqjIrlIZIxcQhNwVLVWK4ElKrpNAmKUMpZaZ5oSMdpUUCMZDATBfm05Rp_IbsWGfNPqGCaRkbnUkFQY6EQJFBr4QLzbRQpdYtwlb8z2cN-Ee-kTQBt3LkFh7lyXPPrfyyRQ63BOW-YxJmkM6wFnnbSM59C0LsZIy3SOIF5K_flbcvBnh18K8dP5In3UHvPD__0j97R542VUlZwMR7srOY1-YDeViV9aFXpN8NNiJR |
linkToPdf | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3LitswFBXtFIZC6Xva9DHVolsPli1ZdndhkjB9JA10Ct0ZyZZDIJFCHMNMVwP9gf5b_2C-pPfKSSaBLkrpzljWtfW858pHR4S8FZWKhFEq4EaIgFciDFQsZRAWPC25YCr0kvlnX-ToW9rro0zOh81emFYfYrvghiPDz9c4wBdltT_IPUMLpmAf5p2g9xIngCfvcEDlSO-L4_F2Vk6k5x9CyJEFUcrifVbPHy3tuap7C1VDrVXtcRc7_moX03qnNHjwP4vzkNxfQ1PabfvSI3LL2MfkcLj--f6E_OrXbm4WS_XdzQyNwuurH_MJdfb66mdp5sqWdFpT5O1SVSBZBjdl0ZWja-nWmuIqPUVu_NQ2rqnpDNyk29hjorU3tfCcoTNnJ2AYHQedKxS1QGUQQ11FjS0dbqa5hHRrJl65nE5UvVo6uOMMHswAsyQUBap01lxsP-Cdt3z6eTjsjnoUGZSXT8nXQf_89CxYnwkRFAANRSDiUJVZoTTgFBOH3BQsVYnhSkitkkKbpAyllJnmhY50lBYJICCBcS7UpynT-IgcWGfNc0IF0zI2OpMKII4EmMggV8KFZlqoUusOYZvmzxet9Ee-EzJBa-XYWniQJ899a-UXHXK8109uMiZhBsEM65Bnbce5SUGBnYzxDkl8__jrd-Xd8TlevfjXjG_I4bg3yD-9H318Se62lKQsYOIVOVgtG_Oa3K7L5tgPo99toSD3 |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Esomeprazole+20%E2%80%83mg+on%E2%80%90demand+is+more+acceptable+to+patients+than+continuous+lansoprazole+15%E2%80%83mg+in+the+long%E2%80%90term+maintenance+of+endoscopy%E2%80%90negative+gastro%E2%80%90oesophageal+reflux+patients%3A+the+COMMAND+Study&rft.jtitle=Alimentary+pharmacology+%26+therapeutics&rft.au=Tsai%2C+H.+H.&rft.au=Chapman%2C+R.&rft.au=Shepherd%2C+A.&rft.au=McKeith%2C+D.&rft.date=2004-09-15&rft.pub=Blackwell+Science+Ltd&rft.issn=0269-2813&rft.eissn=1365-2036&rft.volume=20&rft.issue=6&rft.spage=657&rft.epage=665&rft_id=info:doi/10.1111%2Fj.1365-2036.2004.02155.x&rft.externalDBID=10.1111%252Fj.1365-2036.2004.02155.x&rft.externalDocID=APT2155 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0269-2813&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0269-2813&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0269-2813&client=summon |